Drug intelligence / Profile preview

OT-C001

Development stage: Phase 1
Lead developer: Onward Therapeutics
Modality: CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous, Intratumoral

Overview

OT-C001 is an allogeneic, off-the-shelf natural killer (NK) cell therapy under development by Onward Therapeutics. It is being developed as a potential immunotherapy for cancer treatment, leveraging the cytotoxic activity of NK cells to target and destroy tumor cells. The therapy is designed to be readily available ("off-the-shelf") and does not require patient-specific cell harvesting or engineering. As of early 2024, OT-C001 remains in preclinical development with a focus on neoplasms (cancers)[1][4].

Other names: allogeneic NK cells

Targets

CD20 (B-lymphocyte antigen CD20)

Beyond the preview

Go deeper on OT-C001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on OT-C001.

Explore the full profile